+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-12-12Number of Pages: 198

Hospital Acquired Infection Treatment Market (Infection Type - Urinary Tract Infections, Ventilator Associated Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infection, ENT Infections, Skin Infection, and Bone Infection; Treatment Type - Antibacterial, Antiviral, Antifungal Treatment, Antiparasitic, Antiprotozoal, and Anti-TB Treatment; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Store, and E-Commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Hospital Acquired Infection Treatment Market: Snapshot

The staggering increase in the geriatric population across the world is working as a primary driver for the global hospital acquired infection treatment market, especially in developed nations from Europe. The market is also being propelled by the growing prevalence of nosocomial infections within the neonatal population, coupled by a general lack of efficient surveillance systems that can be used to detect HAIs. Emerging economies are known to be ripe grounds for the proliferation of players in the global hospital acquired infection treatment market due to an overall lack of hygienic conditions within healthcare organizations and the high chances of improper sterilization.

The global hospital acquired infection treatment market was valued at US$28.99 bn at the end of 2015 and is expected to expand at a CAGR of 2.7% within a forecast period from 2016 to 2024. By the end of 2024, this market is expected to reach an estimated US$36.61 bn.

hospital acquired infection treatment market

Antibacterial Treatment for HAIs in Full Swing

The global hospital acquired infection treatment market can be segmented on the basis of treatment has been classified into antibacterial, antiviral, antifungal, and other treatments. In 2015, the antibacterial drugs segment held the leading share in the global hospital acquired infection treatment market. It is also expected to be the leading segment in the global hospital acquired infection treatment market in terms of growth rate within the forecast period from 2016 to 2024. The global hospital acquired infection treatment market has been also classified on the basis of common infection types, into urinary tract infections, hospital-acquired pneumonia, bloodstream infections, surgical site infections, and other. In 2015, hospital acquired pneumonia segment led the global hospital infection therapeutics market in terms of share size. Urinary tract infections segment is expected to be the leading segment in terms of growth rate during the forecast period of 2016 to 2024.

North America likely to Continue Lead in Global Hospital Acquired Infection Treatment Market

North America led the global hospital acquired infection treatment market in 2015, followed by the Europe. The top drivers of the markets in these regions were the high prevalence of various nosocomial infections, the growing number of multi-drug resistant microbial pathogens, the growing demand for advanced therapeutics against the said pathogens, and the greater ratio of hospitals per thousand people, particularly in North America. Europe comprises a very large geriatric demographic for this market, as the elderly are known to be extremely prone to serious and even deadly nosocomial infections as a result of their lowered immunity levels. The elderly therefore are in a greater need of advanced antimicrobial therapeutics, consequently contributing towards the growth of hospital acquired infection treatment market here.

Asia-Pacific represents the leading region in the global hospital acquired infection treatment market on the basis of growth rate, from 2016 to 2024. The leading factor attributed for the high pace of growth of this market is an increasing prevalence of nosocomial infections in the region. Additionally, increasing awareness of nosocomial infections and a constantly evolving healthcare infrastructure, coupled with an increasing expenditure on the healthcare industry will add to the growth of this market in the region.

The top players in the global hospital acquired infection treatment market currently, include Abbott Laboratories, Bayer AG, Pfizer Inc., AstraZeneca Plc., GlaxoSmithKline Plc., Cubist Pharmaceuticals, Inc., Cepheid, Merck & Co., Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc.,Pfizer, Inc., Cipla Inc., Daiichi Sankyo, Inc., Aridis Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and  F. Hoffmann-La Roche Ltd.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation     
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Hospital Acquired Infection Treatment Market 

4. Market Definition
     4.1. Introduction
             4.1.1. Product Definition
             4.1.2. Industry Evolution / Developments
     4.2. Market Overview
     4.3. Key Market Indicators
     4.4. Market Dynamics
             4.4.1. Drivers
                      4.4.1.1. Rising Geriatric Population  
                      4.4.1.2. Unhygienic Conditions and Improper Sterilization Treatment
                      4.4.1.3. Lack of Surveillance Systems for HAIs
                      4.4.1.4. High Susceptibility of Neonatal Population
                      4.4.1.5. High Prevalence of Various Hospital Infections Is Driving the Demand for Anti-infective Drugs
                      4.4.1.6. Government Support in Research and Development of Antibacterial Drugs
             4.4.2. Restraints
                      4.4.2.1. Multi-drug Resistant Bacteria Making Presently Available Antibacterial Drugs Outdated
                      4.4.2.2. Complex Regulatory Requirements
                      4.4.2.3. Government Scrutinizing Hospital Policies to Limit HAIs
                      4.4.2.4. Patent Expirations and Subsequent Launch of Generics
             4.4.3. Opportunities
                      4.4.3.1. Technological Progression
                      4.4.3.2. High Unmet Needs in Low and Medium Income Countries
                      4.4.3.3. High Number of Pipeline Drug Molecules
     4.5. Hospital Acquired Infection Treatment Market Analysis and Forecast, 2016 – 2024
             4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Porter’s Five Force Analysis For Antibacterial Treatment
     4.7. Guidelines for Hospital Acquired Infection Treatment
     4.8. Epidemiology of Hospital Acquired Infection, By Key Countries
     4.9. Regulations for Controlling Hospital Acquired Infection, By Region
     4.10. Future Market Outlook

5. Hospital Acquired Infection Treatment Market Analysis and Forecast, By Infection Type 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Market Size (US$ Mn) Forecast, By Infection Type 
             5.3.1. Urinary Tract Infection 
             5.3.2. Ventilator-Associated Pneumonia
             5.3.3. Bloodstream Infection
             5.3.4. Surgical Site Infection
             5.3.5. Other
     5.4. Market Attractiveness By Infection Type 

6. Hospital Acquired Infection Treatment Market Analysis and Forecasts, By Treatment 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Size (US$ Mn) Forecast, By Treatment 
             6.3.1. Antibacterial Treatment 
                      6.3.1.1. Beta-Lactams
                      6.3.1.2. Quinolones
                      6.3.1.3. Vancomycin
                      6.3.1.4. Other
             6.3.2. Antiviral Treatment
                      6.3.2.1. Acyclovir
                      6.3.2.2. Foscarnet
             6.3.3. Antifungal Treatment
                      6.3.3.1. Amphotericin B
                      6.3.3.2. Triazoles
             6.3.4. Other
     6.4. Market Attractiveness By Treatment 

7. Hospital Acquired Infection Treatment Market Analysis and Forecasts, By Distribution Channel
     7.1. Introduction & Definition
     7.2. Key Findings / Developments     
     7.3. Market Size (US$ Mn) Forecast, By Distribution Channel 
             7.3.1. Hospital Pharmacies
             7.3.2. Retail Pharmacies
             7.3.3. Drug Store
             7.3.4. E-Commerce
             7.3.5. Other
     7.4. Market Attractiveness By Distribution Channel

8. Hospital Acquired Infection Treatment Market Analysis and Forecasts, By Region
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Key Trends
     8.4. Market Size (US$ Mn) Forecast, By Region
             8.4.1. North America
             8.4.2. Europe
             8.4.3. Asia Pacific
             8.4.4. Latin America
             8.4.5. Middle East and Africa
     8.5. Market Attractiveness By Country/Region

9. North America Hospital Acquired Infection Treatment Market Analysis and Forecast
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Key Trends
     9.4. Market Size (US$ Mn) Forecast, By Country
             9.4.1. U.S.
             9.4.2. Canada
     9.5. Market Size (US$ Mn) Forecast, By Infection Type 
             9.5.1. Urinary Tract Infection 
             9.5.2. Ventilator-Associated Pneumonia
             9.5.3. Bloodstream Infection
             9.5.4. Surgical Site Infection
             9.5.5. Other
     9.6. Market Size (US$ Mn) Forecast, By Treatment
             9.6.1. Antibacterial Treatment 
                      9.6.1.1. Beta-Lactams
                      9.6.1.2. Quinolones
                      9.6.1.3. Vancomycin
                      9.6.1.4. Other
             9.6.2. Antiviral Treatment
                      9.6.2.1. Acyclovir
                      9.6.2.2. Foscarnet
             9.6.3. Antifungal Treatment
                      9.6.3.1. Amphotericin B
                      9.6.3.2. Triazoles
             9.6.4. Other
     9.7. Market Size (US$ Mn) Forecast, By Distribution Channel 
             9.7.1. Hospital Pharmacies
             9.7.2. Retail Pharmacies
             9.7.3. Drug Store
             9.7.4. E-Commerce
             9.7.5. Other
     9.8. Market Attractiveness Analysis 
             9.8.1. By Country
             9.8.2. By Infection Type
             9.8.3. By Treatment 
             9.8.4. By Distribution Channel

10. Europe Hospital Acquired Infection Treatment Market Analysis and Forecast
     10.1. Introduction & Definition
     10.2. Key Findings / Developments
     10.3. Key Trends
     10.4. Market Size (US$ Mn) Forecast, By Country
             10.4.1. Germany
             10.4.2. France
             10.4.3. U.K.
             10.4.4. Italy 
             10.4.5. Spain
             10.4.6. Rest of Europe
     10.5. Market Size (US$ Mn) Forecast, By Infection Type 
             10.5.1. Urinary Tract Infection 
             10.5.2. Ventilator-Associated Pneumonia
             10.5.3. Bloodstream Infection
             10.5.4. Surgical Site Infection
             10.5.5. Other
     10.6. Market Size (US$ Mn) Forecast, By Treatment
             10.6.1. Antibacterial Treatment 
                      10.6.1.1. Beta-Lactams
                      10.6.1.2. Quinolones
                      10.6.1.3. Vancomycin
                      10.6.1.4. Other
             10.6.2. Antiviral Treatment
                      10.6.2.1. Acyclovir
                      10.6.2.2. Foscarnet
             10.6.3. Antifungal Treatment
                      10.6.3.1. Amphotericin B
                      10.6.3.2. Triazoles
             10.6.4. Other 
     10.7. Market Size (US$ Mn) Forecast, By Distribution Channel 
             10.7.1. Hospital Pharmacies
             10.7.2. Retail Pharmacies
             10.7.3. Drug Store
             10.7.4. E-Commerce
             10.7.5. Other
     10.8. Market Attractiveness Analysis 
             10.8.1. By Country
             10.8.2. By Infection Type
             10.8.3. By Treatment 
             10.8.4. By Distribution Channel

11. Asia Pacific Hospital Acquired Infection Treatment Market Analysis and Forecast
     11.1. Introduction & Definition
     11.2. Key Findings / Developments
     11.3. Key Trends
     11.4. Market Size (US$ Mn) Forecast, By Country
             11.4.1. Japan
             11.4.2. China
             11.4.3. India
             11.4.4. Australia
             11.4.5. Rest of Asia Pacific
     11.5. Market Size (US$ Mn) Forecast, By Infection Type 
             11.5.1. Urinary Tract Infection 
             11.5.2. Ventilator-Associated Pneumonia
             11.5.3. Bloodstream Infection
             11.5.4. Surgical Site Infection
             11.5.5. Other
     11.6. Market Size (US$ Mn) Forecast, By Treatment
             11.6.1. Antibacterial Treatment 
                      11.6.1.1. Beta-Lactams
                      11.6.1.2. Quinolones
                      11.6.1.3. Vancomycin
                      11.6.1.4. Other
             11.6.2. Antiviral Treatment
                      11.6.2.1. Acyclovir
                      11.6.2.2. Foscarnet
             11.6.3. Antifungal Treatment
                      11.6.3.1. Amphotericin B
                      11.6.3.2. Triazoles
             11.6.4. Other 
     11.7. Market Size (US$ Mn) Forecast, By Distribution Channel 
             11.7.1. Hospital Pharmacies
             11.7.2. Retail Pharmacies
             11.7.3. Drug Store
             11.7.4. E-Commerce
             11.7.5. Other
     11.8. Market Attractiveness Analysis 
             11.8.1. By Country
             11.8.2. By Infection Type
             11.8.3. By Treatment 
             11.8.4. By Distribution Channel

12. Latin America Hospital Acquired Infection Treatment Market Analysis and Forecast
     12.1. Introduction & Definition
     12.2. Key Findings / Developments
     12.3. Key Trends
     12.4. Market Size (US$ Mn) Forecast, By Country
             12.4.1. Brazil
             12.4.2. Mexico
             12.4.3. Rest of Latin America 
     12.5. Market Size (US$ Mn) Forecast, By Infection Type 
             12.5.1. Urinary Tract Infection
             12.5.2. Ventilator-Associated Pneumonia
             12.5.3. Bloodstream Infection
             12.5.4. Surgical Site Infection
             12.5.5. Other
     12.6. Market Size (US$ Mn) Forecast, By Treatment
             12.6.1. Antibacterial Treatment 
                      12.6.1.1. Beta-Lactams
                      12.6.1.2. Quinolones
                      12.6.1.3. Vancomycin
                      12.6.1.4. Other
             12.6.2. Antiviral Treatment
                      12.6.2.1. Acyclovir
                      12.6.2.2. Foscarnet
             12.6.3. Antifungal Treatment
                      12.6.3.1. Amphotericin B
                      12.6.3.2. Triazoles
             12.6.4. Other 
     12.7. Market Size (US$ Mn) Forecast, By Distribution Channel 
             12.7.1. Hospital Pharmacies
             12.7.2. Retail Pharmacies
             12.7.3. Drug Store
             12.7.4. E-Commerce
             12.7.5. Other
     12.8. Market Attractiveness Analysis 
             12.8.1. By Country
             12.8.2. By Infection Type
             12.8.3. By Treatment 
             12.8.4. By Distribution Channel

13. Middle East & Africa (MEA) Hospital Acquired Infection Treatment Market Analysis and Forecast
     13.1. Introduction & Definition
     13.2. Key Findings / Developments
     13.3. Key Trends
     13.4. Market Size (US$ Mn) Forecast, By Country
             13.4.1. Saudi Arabia
             13.4.2. South Africa
             13.4.3. Rest of MEA
     13.5. Market Size (US$ Mn) Forecast, By Infection Type 
             13.5.1. Urinary Tract Infection 
             13.5.2. Ventilator-Associated Pneumonia
             13.5.3. Bloodstream Infection
             13.5.4. Surgical Site Infection
             13.5.5. Other
     13.6. Market Size (US$ Mn) Forecast, By Treatment
             13.6.1. Antibacterial Treatment 
                      13.6.1.1. Beta-Lactams
                      13.6.1.2. Quinolones
                      13.6.1.3. Vancomycin
                      13.6.1.4. Other
             13.6.2. Antiviral Treatment
                      13.6.2.1. Acyclovir
                      13.6.2.2. Foscarnet
             13.6.3. Antifungal Treatment
                      13.6.3.1. Amphotericin B
                      13.6.3.2. Triazoles
             13.6.4. Other 
     13.7. Market Size (US$ Mn) Forecast, By Distribution Channel 
             13.7.1. Hospital Pharmacies
             13.7.2. Retail Pharmacies
             13.7.3. Drug Store
             13.7.4. E-Commerce
             13.7.5. Other
    13.8. Market Attractiveness Analysis 
             13.8.1. By Country
             13.8.2. By Infection Type
             13.8.3. By Treatment 
             13.8.4. By Distribution Channel

14. Competition Landscape
     14.1. Market Player – Competition Matrix (By Tier and Size of companies)
     14.2. Company Share Analysis (2016)
     14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
             14.3.1. Abbott Laboratories
                      14.3.1.1. Company Overview
                      14.3.1.2. Business Overview
                      14.3.1.3. Financial Overview
                      14.3.1.4. SWOT Analysis
                      14.3.1.5. Strategic Overview
             14.3.2. Pfizer Inc. 
                      14.3.2.1. Company Overview
                      14.3.2.2. Business Overview
                      14.3.2.3. Financial Overview
                      14.3.2.4. SWOT Analysis
                      14.3.2.5. Strategic Overview
             14.3.3. Bayer AG
                      14.3.3.1. Company Overview
                      14.3.3.2. Business Overview
                      14.3.3.3. Financial Overview
                      14.3.3.4. SWOT Analysis
                      14.3.3.5. Strategic Overview
             14.3.4. Cepheid
                      14.3.4.1. Company Overview
                      14.3.4.2. Business Overview
                      14.3.4.3. Financial Overview
                      14.3.4.4. SWOT Analysis
                      14.3.4.5. Strategic Overview
             14.3.5. AstraZeneca plc
                      14.3.5.1. Company Overview
                      14.3.5.2. Business Overview
                      14.3.5.3. Financial Overview
                      14.3.5.4. SWOT Analysis
                      14.3.5.5. Strategic Overview
             14.3.6. F. Hoffmann-La Roche Ltd.
                      14.3.6.1. Company Overview
                      14.3.6.2. Business Overview
                      14.3.6.3. Financial Overview
                      14.3.6.4. SWOT Analysis
                      14.3.6.5. Strategic Overview
             14.3.7. Johnson & Johnson Services, Inc.
                      14.3.7.1. Company Overview
                      14.3.7.2. Business Overview
                      14.3.7.3. Financial Overview
                      14.3.7.4. SWOT Analysis
                      14.3.7.5. Strategic Overview
             14.3.8. Merck & Co., Inc. 
                      14.3.8.1. Company Overview
                      14.3.8.2. Business Overview
                      14.3.8.3. Financial Overview
                      14.3.8.4. SWOT Analysis
                      14.3.8.5. Strategic Overview
             14.3.9. Cipla Inc.
                      14.3.9.1. Company Overview
                      14.3.9.2. Business Overview
                      14.3.9.3. Financial Overview
                      14.3.9.4. SWOT Analysis
                      14.3.9.5. Strategic Overview
             14.3.10. GlaxoSmithKline plc
                      14.3.10.1. Company Overview
                      14.3.10.2. Business Overview
                      14.3.10.3. Financial Overview
                      14.3.10.4. SWOT Analysis
                      14.3.10.5. Strategic Overview
             14.3.11. Aridis Pharmaceuticals, Inc.
                      14.3.11.1. Company Overview
                      14.3.11.2. Business Overview
                      14.3.11.3. Financial Overview
                      14.3.11.4. SWOT Analysis
                      14.3.11.5. Strategic Overview
             14.3.12. Astellas Pharma Inc.
                      14.3.12.1. Company Overview
                      14.3.12.2. Business Overview
                      14.3.12.3. Financial Overview
                      14.3.12.4. SWOT Analysis
                      14.3.12.5. Strategic Overview
             14.3.13. Daiichi Sankyo, Inc.
                      14.3.13.1. Company Overview
                      14.3.13.2. Business Overview
                      14.3.13.3. Financial Overview
                      14.3.13.4. SWOT Analysis
                      14.3.13.5. Strategic Overview
             14.3.14. Bristol-Myers Squibb Company
                      14.3.14.1. Company Overview
                      14.3.14.2. Business Overview
                      14.3.14.3. Financial Overview
                      14.3.14.4. SWOT Analysis
                      14.3.14.5. Strategic Overview
             14.3.15. Eli Lilly and Company
                      14.3.15.1. Company Overview
                      14.3.15.2. Business Overview
                      14.3.15.3. Financial Overview
                      14.3.15.4. SWOT Analysis
                      14.3.15.5. Strategic Overview

List of Figures

Figure 01: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024
Figure 03: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Ventilator-associated Pneumonia (VAP)
Figure 02: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Urinary Tract Infection
Figure 05: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Surgical Site Infection
Figure 04: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Bloodstream Infection
Figure 06: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Other Infections
Figure 07: Global Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2016–2024
Figure 08: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) Share Analysis, by Infection Type, 2016 and 2024
Figure 09: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antibacterial Treatment
Figure 10: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antiviral Treatment
Figure 11: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antifungal Treatment
Figure 12: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Other Treatments
Figure 13: Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2016–2024
Figure 14: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) Share Analysis, by Treatment, 2016 and 2024
Figure 15: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Hospital Pharmacies
Figure 16: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Retail Pharmacies 
Figure 17: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Drug Stores
Figure 18: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by E-commerce
Figure 19: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Other Distribution Channels
Figure 20: Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 21: Global Hospital Acquired Infection Treatment Market Value (US$ Mn) Share Analysis, by Distribution Channel, 2016 and 2024
Figure 22: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 23: North America Hospital Acquired Infection Treatment Market Size Y-o-Y Growth Projections, 2016–2024
Figure 24: U.S. Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 25: Canada Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 26: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Urinary Tract Infection
Figure 27: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Ventilator-Associated Pneumonia (VAP)
Figure 28: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Bloodstream Infection
Figure 29: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Surgical Site Infection
Figure 30: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 31: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antibacterial Treatment
Figure 32: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antiviral Treatment
Figure 33: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antifungal Treatment
Figure 34: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 35: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Hospital Pharmacies
Figure 36: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Retail Pharmacies
Figure 37: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Drug Stores
Figure 38: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by E-commerce
Figure 39: North America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 40: North America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Country, 2016–2024
Figure 41: North America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2016–2024
Figure 42: North America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2016–2024
Figure 43: North America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 44: Europe Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 45: Europe Hospital-acquired Infection Treatment Market Size, Y-o-Y Growth Projections, 2016–2024
Figure 46: Germany Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 47: The U.K. Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 48: France Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 49: Spain Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 50: Italy Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 51: Rest of Europe Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 52: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Urinary Tract Infection, 2016–2024
Figure 53: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Ventilator-associated Pneumonia (VAP), 2016–2024
Figure 54: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Bloodstream Infection, 2016–2024
Figure 55: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Surgical Site Infection, 2016–2024
Figure 56: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), by Others, 2016–2024
Figure 57: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), 2016–2024, by Antibacterial Treatment
Figure 58: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), 2016–2024, by Antiviral Treatment
Figure 59: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), 2016–2024, by Antifungal Treatment
Figure 60: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) Forecast & Y-o-Y Growth (%), 2016–2024, by Others
Figure 61: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2016–2024
Figure 62: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2016–2024
Figure 63: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by Drug Stores, 2016–2024
Figure 64: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by E-commerce, 2016–2024
Figure 65: Europe Hospital-acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, by Others, 2016–2024
Figure 66: Europe Hospital-acquired Infection Treatment Market Attractiveness Analysis, by Country, 2016–2024
Figure 67: Europe Hospital-acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2016–2024
Figure 68: Europe Hospital-acquired Infection Treatment Market Attractiveness Analysis, by Treatment Type, 2016–2024
Figure 69: Europe Hospital-acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 70: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 71: Asia Pacific Hospital Acquired Infection Treatment Market Size Y-o-Y Growth Projections, 2016–2024
Figure 72: Japan Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 73: China Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 74: India Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 75: Australia Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 76: Rest of APAC Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 77: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Urinary Tract Infection
Figure 78: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Ventilator-associated Pneumonia (VAP)
Figure 79: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Bloodstream Infection
Figure 80: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Surgical Site Infection
Figure 81: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 82: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antibacterial Treatment
Figure 83: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antiviral Treatment
Figure 84: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antifungal Treatment
Figure 85: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 86: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Hospital Pharmacies
Figure 87: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Retail Pharmacies
Figure 88: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Drug Stores
Figure 89: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by E-commerce
Figure 90: Asia Pacific Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 91: Asia Pacific Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Country, 2016–2024
Figure 92: Asia Pacific Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2016–2024
Figure 93: Asia Pacific Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2016–2024
Figure 94: Asia Pacific Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 95: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 96: Latin America Hospital Acquired Infection Treatment Market Size Y-o-Y Growth Projections, 2016–2024
Figure 97: Brazil Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 98: Mexico Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 99: Rest of Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 100: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Urinary Tract Infection
Figure 101: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Ventilator-Associated Pneumonia (VAP)
Figure 102: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Bloodstream Infection
Figure 103: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Surgical Site Infection
Figure 104: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 105: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antibacterial Treatment
Figure 106: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antiviral Treatment
Figure 107: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antifungal Treatment
Figure 108: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 109: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Hospital Pharmacies
Figure 110: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Retail Pharmacies
Figure 111: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Drug Stores
Figure 112: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by E-Commerce
Figure 113: Latin America Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 114: Latin America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Country, 2016–2024
Figure 115: Latin America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2016–2024
Figure 116: Latin America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2016–2024
Figure 117: Latin America Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 118: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 119: Middle East & Africa Hospital Acquired Infection Treatment Market Size Y-o-Y Growth Projections, 2016–2024
Figure 120: South Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 121: UAE Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 122: Rest of Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, 2016–2024
Figure 123: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Urinary Tract Infection
Figure 124: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Ventilator-associated Pneumonia (VAP)
Figure 125: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Bloodstream Infection
Figure 126: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Surgical Site Infection
Figure 127: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 128: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antibacterial Treatment
Figure 129: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antiviral Treatment
Figure 130: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Antifungal Treatment
Figure 131: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 132: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Hospital Pharmacies
Figure 133: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Retail Pharmacies
Figure 134: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Drug Stores
Figure 135: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by E-commerce
Figure 136: Middle East & Africa Hospital Acquired Infection Treatment Market Value (US$ Mn) & Y-o-Y Growth (%) Forecast, 2016–2024, by Others
Figure 137: Middle East & Africa Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Country, 2016–2024
Figure 138: Middle East & Africa Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Infection Type, 2016–2024
Figure 139: Middle East & Africa Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Treatment, 2016–2024
Figure 140: Middle East & Africa Hospital Acquired Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2016–2024

List of Tables

Table 01: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2016–2024
Table 02: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2016–2024
Table 03: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2016–2024
Table 04: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2016–2024
Table 05: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Others, 2016–2024
Table 06: Global Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 07: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2016–2024
Table 08: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2016–2024
Table 09: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2016–2024
Table 10: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2016–2024
Table 11: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Other Treatments, 2016–2024
Table 12: North America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 13: Europe Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2016–2024
Table 14: Europe Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2016–2024
Table 15: Europe Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2016–2024
Table 16: Europe Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2016–2024
Table 17: Europe Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2016–2024
Table 18: Europe Hospital-acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 19: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2016–2024
Table 20: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2016–2024
Table 21: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2016–2024
Table 22: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2016–2024
Table 23: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Others, 2016–2024
Table 24: Asia Pacific Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024
Table 25: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2016–2024
Table 26: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2016–2024
Table 27: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2016–2024
Table 28: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2016–2024
Table 29: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Others, 2016–2024
Table 30: Latin America Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel,
Table 31: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Infection Type, 2016–2024
Table 32: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antibacterial Treatment, 2016–2024
Table 33: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antiviral Treatment, 2016–2024
Table 34: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Antifungal Treatment, 2016–2024
Table 35: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Others, 2016–2024
Table 36: Middle East & Africa Hospital Acquired Infection Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2024

Global Hospital Acquired Infection Treatment Market: Overview

This report on hospital acquired infection treatment, studies the current as well as future prospects of the market globally. Hospital infections are also referred to as healthcare-associated infections (HAIs), or nosocomial infections or hospital-acquired infection (HAIs). HAIs can be defined as those infections that occur in patients when they are admitted to a hospital or any other health-care facility with which they were not suffering from at the time of their admission. Hospital acquired infection also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. Several antimicrobial drugs have proven their effectiveness in treating a range of hospital infections that are globally prevalent at present.

Global Hospital Acquired Infection Treatment Market: Research Methodologies

The report is a combination of primary and secondary research. Primary research formed the bulk of our research efforts, with information collected from telephonic interviews and interactions via e-mail. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various national and international databases. The report provides market size in terms of US$ Mn for each segment for the period from 2016 to 2024, considering the macro and micro-environmental factors. Growth rates for each segment within the hospital acquired infection treatment market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, expenditure, and regulatory requirements.

The market overview section of the report includes qualitative analysis of the overall hospital acquired infection treatment market including the determining factors and market dynamics such as drivers, restraints, market trends and opportunities, along with white space analysis. In addition, market attractiveness analysis by country, isotopic application and end-user along with competitive landscape by key players have been provided which explain the intensity of competition in the market considering different geographical locations. The competitive scenario between market players has been evaluated through market share analysis. These factors would help the market players take strategic decisions in order to strengthen their positions and increase their shares in the global market.

Global Hospital Acquired Infection Treatment Market: Scope of the Study

The market for hospital acquired infection treatment is segmented into antibacterial, antiviral, antifungal treatment and other treatment. Antibacterial treatment segment is expected to be most attractive segment during the forecast period. Increased consumption of antibiotics globally is fueling the growth of this segment. The hospital infection therapeutics market is also segmented on the basis of infection types, which includes urinary tract infections, hospital-acquired pneumonia, bloodstream infections, surgical site infections and other infections. Urinary tract infection is among the most common hospital acquired infection affecting millions of people worldwide which shows high CAGR during the forecast period. The retail pharmacies segment accounted for the major share of global hospital acquired infection treatment market. Increasing healthcare awareness and development of new antibiotics due to completion in key players is driving demand for the segment.

Geographically, the hospital infection therapeutics market has been categorized into five regions namely, North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Asia Pacific has the highest growth rate and is expected to overtake Europe in the future. The major factor responsible for high growth rate are rapidly increasing prevalence of hospital-acquired infections in the region, due to unhygienic conditions and improper sterilization treatment. The market size and forecast for each of these regions has been provided for the period 2016 to 2024.

Global Hospital Acquired Infection Treatment Market: Competitive Landscape

A list of recommendations has been provided for new entrants as well as existing market players to help them establish a strong presence in the market and increase their share. The report also profiles major players of the hospital acquired infection treatment market on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments.

Some of the major players profiled in this report include Abbott , AstraZeneca plc, Bayer AG, Pfizer Inc., Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Cepheid, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Cipla Inc., Astellas Pharma Inc., Aridis Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche Ltd.

The Global Hospital Acquired Infection Treatment Market is segmented as follows:

Global Hospital Acquired Infection Treatment Market, by Infection Type

  • Urinary Tract Infections
  • Ventilator Associated Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Other Hospital Infections (Gastrointestinal Infection, ENT Infections, Skin Infection and Bone Infection)

Global Hospital Acquired Infection Treatment Market, by Treatment

  • Antibacterial Treatment
    • Beta-Lactams
    • Quinolones
    • Vancomycin
    • Other
  • Antiviral Treatment
    • Acyclovir
    • Foscarnet
  • Antifungal Treatment
    • Amphotericin B
    • Triazoles
  • Other (Antiparasitic, Antiprotozoal and Anti TB Treatment)

Global Hospital Acquired Infection Treatment Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • E-Commerce
  • Other

Hospital Infection Therapeutics Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa


 
 
Back To Top